Sorrento Therapeutics, Inc.
SRNE · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Market Cap | $4 | $14 | $16 | $5 |
| - Cash | $24 | $37 | $56 | $23 |
| + Debt | $135 | $238 | $169 | $294 |
| Enterprise Value | $115 | $215 | $129 | $276 |
| Revenue | $63 | $53 | $40 | $31 |
| % Growth | 18.8% | 32.3% | 27.2% | – |
| Gross Profit | $29 | $40 | $30 | $19 |
| % Margin | 46.8% | 75.4% | 75.1% | 61.1% |
| EBITDA | -$540 | -$436 | -$276 | -$308 |
| % Margin | -859.2% | -824.1% | -689.5% | -981.1% |
| Net Income | -$573 | -$429 | -$298 | -$359 |
| % Margin | -911.6% | -810.9% | -746.4% | -1,142.5% |
| EPS Diluted | -1.37 | -1.46 | -1.3 | -2.56 |
| % Growth | 6.2% | -12.3% | 49.2% | – |
| Operating Cash Flow | -$294 | -$282 | -$160 | -$173 |
| Capital Expenditures | -$14 | -$9 | -$38 | -$11 |
| Free Cash Flow | -$308 | -$291 | -$197 | -$184 |